 |
|
Markets |
|
Target Market - Bio-Tech / Pharmaceuticals
Target Market - Healthcare
|
Subsequent markets include:
- Pharmaceuticals & Contract Research Organizations involved in clinical trials related to diabetes or skin diseases
- Doctors & Hospitals practices and providers specializing in other forms of Arthritis, diabetes and skin diseases
- Assisted Healthcare organizations that care for long-terms patients suffering from Lesion formations and pressure ulcers. There are currently 18,000 assisted living and skilled nursing organizations in the US.
- Research institutions involved in development of bio-markers
|
 |
|
Initial Markets:
|
| |
|
Initial entry to the market for the Arthritis Imager™ will be through Biotech and pharmaceutical organizations involved in
clinical trials related to Rheumatoid Arthritis drugs. The Arthritis Imager™ will provide objective measures and patient
documentation to substantially reduce required trial size, time to market, and quantify the efficacy of the developing drug.
Using the economic drivers of the Biotech and Pharmaceutical markets, we will then target doctor practices and hospitals that
specialize in treating arthritis.
|
| |
|
Subsequent Markets:
|
| |
In addition to Rheumatoid Arthritis, the Cartesia Dx technology can be expanded to other diseases that manifest as surface
inflammation. Our subsequent target markets include:
- Other forms of Arthritis
- Lesion formation that results from Diabetes and other Skin Diseases
- Pressure Ulcers formation such as bed sores
|